Stemline Therapeutics (STML) Now Covered by Roth Capital

Roth Capital began coverage on shares of Stemline Therapeutics (NASDAQ:STML) in a report released on Tuesday, The Fly reports. The firm set a “buy” rating and a $30.00 price target on the biopharmaceutical company’s stock. Roth Capital’s price target would indicate a potential upside of 60.86% from the company’s previous close.

A number of other analysts have also recently weighed in on STML. ValuEngine raised shares of Stemline Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 2nd. HC Wainwright set a $38.00 price objective on shares of Stemline Therapeutics and gave the stock a “buy” rating in a report on Wednesday, June 6th. BidaskClub cut shares of Stemline Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Friday. Wedbush raised their target price on shares of Stemline Therapeutics from $20.00 to $22.00 and gave the company an “outperform” rating in a research note on Tuesday, May 29th. Finally, Zacks Investment Research raised shares of Stemline Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, May 22nd. One investment analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. Stemline Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $30.00.

STML stock opened at $18.65 on Tuesday. Stemline Therapeutics has a fifty-two week low of $7.30 and a fifty-two week high of $20.55. The stock has a market capitalization of $552.50 million and a P/E ratio of -6.34.



Stemline Therapeutics (NASDAQ:STML) last released its quarterly earnings data on Friday, March 16th. The biopharmaceutical company reported ($0.93) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.67) by ($0.26). Stemline Therapeutics had a negative return on equity of 101.93% and a negative net margin of 4,689.63%. analysts expect that Stemline Therapeutics will post -2.78 earnings per share for the current year.

Institutional investors have recently added to or reduced their stakes in the business. Royce & Associates LP bought a new position in shares of Stemline Therapeutics during the 4th quarter valued at about $106,000. Two Sigma Investments LP bought a new position in shares of Stemline Therapeutics during the 4th quarter valued at about $170,000. MetLife Investment Advisors LLC bought a new position in shares of Stemline Therapeutics during the 4th quarter valued at about $186,000. Raymond James Financial Services Advisors Inc. bought a new position in shares of Stemline Therapeutics during the 4th quarter valued at about $189,000. Finally, Sofinnova Ventures Inc bought a new position in shares of Stemline Therapeutics during the 1st quarter valued at about $193,000. 66.91% of the stock is currently owned by hedge funds and other institutional investors.

About Stemline Therapeutics

Stemline Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of proprietary oncology therapeutics in the United States and internationally. The company develops SL-401, a targeted therapy directed to the interleukin-3 receptor (IL-3R), which has completed Phase II clinical trial for patients with blastic plasmacytoid dendritic cell neoplasm; is in Phase I/II clinical trials for patients with myeloproliferative neoplasms, chronic myelomonocytic leukemia, myelofibrosis, and acute myeloid leukemia; and is in Phase I clinical trial in combination with other agents for patients with relapsed/refractory multiple myeloma.

The Fly

Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply